

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

The board of directors (the “**Board**”) of China Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that, at the ceremony of the 2012 State Science and Technology Awards held on 18 January 2013, the Levamlodipine Maleate (commodity name “Xuanning”) raw materials and preparations (馬來酸左旋氨氯地平(商品名：「玄寧」)原料與製劑) project researched and developed by the Company’s subsidiary was awarded the 2012 State Technological Invention Award (Second Class) (二零一二年度國家技術發明二等獎) by the State Council of the People’s Republic of China (the “**State Council**”).

The State Technological Invention Award (國家技術發明獎) is one of the five State Science and Technology Awards initiated by the State Council and is assessed annually. According to the Regulations on State Science and Technology Awards (《國家科學技術獎勵條例》) promulgated by the State Council, the State Technological Invention Award will be awarded to citizens who make significant technological inventions such as products, industrial techniques, materials and their related systems by applying the knowledge of science and technology. Such significant technological invention should meet the following criteria:

- (1) the invention has not yet previously been invented or made public;
- (2) the invention is original and creative; and
- (3) upon implementation, the invention will produce considerable economic returns or social benefits.

According to the Detailed Rules for the Implementation of the Regulations on State Science and Technology Awards (《國家科學技術獎勵條理實施細則》), the assessment criteria of the State Technological Invention Award (Second Class) are as follows: a significant technological invention pioneering among domestic and overseas inventions, its technological thought being novel, its major technology being relatively innovative, its technological and economic indicators reaching an advanced level among technologies of the same type, which has promoted technological progress in its field and has brought about obvious economic returns or social benefits.

By Order of the Board of
China Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 21 January 2013

As at the date of this announcement, the Board of the Company comprises Mr. Cai Dongchen, Mr. Feng Zhenying, Mr. Chak Kin Man, Mr. Pan Weidong, Mr. Zhao John Huan, Mr. Wang Shunlong, Mr. Wang Huaiyu, Mr. Lu Jianmin and Mr. Wang Zhenguo as executive directors; Mr. Lee Ka Sze, Carmelo as non-executive director and Mr. Huo Zhenxing, Mr. Qi Moujia, Mr. Guo Shichang, Mr. Chan Siu Keung, Leonard, Mr. Wang Bo and Mr. Zhang Fawang as independent non-executive directors.